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model. Results: Over the entire 3-year period with gradually interchanging 80% of 
infliximab patients to biosimilar infliximab is expected to leading to a net benefit of 
29,810,000 euros compared to the scenario in which biosimilar infliximab would not 
be available. In the scenario in which interchangeabilty was disallowed the budget 
savings was 18,765,000 euros. If budget savings were spent on reimbursement of 
additional biosimilar treatments, approximately 1,615 or 1,025 more patients could 
be treated in the six countries, respectively. ConClusions: This budget impact 
analysis indicates that introducing biosimilar infliximab might result significant 
budget savings or increasing of the number of patient access to biological therapy. 
Interchanging by prescribing physicians could substantially increase budget savings.
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objeCtives: Biosimilars have similar efficacy and safety profiles to the originator 
biologics such that their introduction into Ireland is expected to increase competi-
tion, lower prices and improve the affordability of costly therapies. The objective 
of this study sought to estimate the budget impact of introducing an infliximab 
biosimilar (CT-P13) as a treatment option for rheumatoid arthritis (RA) patients 
in Ireland. Methods: An Excel-based budget impact model was developed over 
a five-year time horizon. The annual population in Ireland receiving treatment 
with a biologic was based on national population statistics and published litera-
ture including: prevalence and incidence of RA; proportion of patients eligible for 
treatment with a biologic; and proportion of patients receiving treatment with a 
biologic. After the first year, an annual population growth rate of 1.1% was assumed. 
Maximum conversion of all existing and new infliximab patients to the infliximab 
biosimilar was assumed for years one to five. The total cost/patient was based on 
published literature and included drug acquisition, administration, and monitoring 
costs. Outcomes are reported as the annual and cumulative budget impact over five 
years. Results: In year one, 3,776 prevalent and 119 incident patients entered the 
model. Of these, 13% received the infliximab biosimilar with the total cost/patient 
calculated as € 15,754 in the first year of treatment and € 12,789 in subsequent years. 
The drug acquisition cost for the infliximab biosimilar was assumed to discount 
infliximab by 20%. Annual budget saving estimations following introduction of the 
infliximab biosimilar were € 579,631, € 1,165,400, € 1,177,553, € 1,189,463 and € 1,201,137 
for years one to five, with a cumulative budget saving of € 5,313,184. ConClusions: 
Introducing an infliximab biosimilar as a treatment option for RA patients in Ireland 
represents a cost saving of up to € 5,313,184 over five years; equivalent to treating 
an extra 337 new patients with a biosimilar for one year.
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objeCtives: Iliac Crest Bone Graft (ICBG) is a commonly used bone graft material 
in lumbar spinal fusion procedures. Demineralised Bone Matrix (DBM) added to 
supplement Local Bone (LB) provides an alternative graft material that does not 
require a secondary surgery site to harvest iliac crest bone. The objective of this 
study was to investigate the economic impact associated with the use of DBM in 
lumbar spinal fusion procedures in the UK. Methods: A decision tree model was 
developed to evaluate the two-year budget impact associated with adding DBM 
as an alternative bone graft material in the lumbar spinal fusion surgical proce-
dure. The model structure was based on previously published economic models, 
identified via a structured literature search, and compares surgical treatment with 
either ICBG or DBM added to the LB procedure. The model includes the costs of the 
surgical procedures, for adverse events and for treatment failure (reoperations). 
Further, the model was validated by UK clinical experts to ensure its adherence to 
UK clinical practice. The model population included UK-based patients with lumbar 
degenerative disc disease (LDDD) considered eligible for lumbar spinal fusion with 
either LB or ICBG. In the model’s base-case analysis, ICBG was compared with DBM 
added to LB. Results: The model predicts cost-savings of £44 467 over two years 
when adding DBM to LB compared with using ICBG alone for the lumbar spinal 
fusion procedure in a hypothetical population of 100 patients. The cost-savings 
are realised through reduced surgical time and fewer adverse events associated 
with surgery. ConClusions: In a defined population of spinal fusion patients 
in the UK that would otherwise be treated with ICBG, the addition of DBM to LB 
presents an economically viable and potentially cost-saving clinically appropriate 
treatment option.
PMS24
PotentIal econoMIc IMPact of uSIng SugaMMadex for the routIne 
reverSal of neuroMuScular blocKade In ruSSIan health care 
SettIng
Derkach E.V.1, Avxentyeva M.V.2, Omelyanovsky V.V.2
1Autonomous Non-profit Organization “National Centre for Health Technology Assessment”, 
Moscow, Russia, 2The Russian Presidential Academy of National Economy and Public 
Administration, Moscow, Russia
objeCtives: To evaluate the potential economic impact of sugammadex used for 
reversal of rocuronium-induced neuromuscular blockade (NMB) in comparison 
with neostigmine and spontaneous reversion of NMB in Russian health care set-
ting. Methods: We constructed the model to compare two scenarios of general 
anesthesia with rocuronium-induced NMB: 1) routine practice (70% spontaneous 
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objeCtives: Venous thromboembolism (VTE) including deep vein thrombosis (DVT) 
and pulmonary embolism (PE) occurs most often in patients undergoing major joint 
arthroplasty and major surgical procedures (such as hip arthroplasty, HA or knee 
arthroplasty, KA). The prevalence of clinically relevant VTE, DVT and PE after hip 
and knee arthroplasty in nationwide database of Korea were 1.7%, 1.1% and 0.5%, 
respectively. The aim of this study was to compare the risk for VTE (including DVT 
and PE) between hip and knee arthroplasty in the Korean population. Methods: A 
retrospective cohort study was conducted using nationwide claim registry obtained 
from the Korean Health Insurance Review and Assessment Service (HIRA), which 
includes medical claims records for 97.0% of South Koreans. We retrospectively 
identified patients who underwent HA or KA between January 1 and December 31 
in 2010. VTE after arthroplasty were identified by diagnostic code (ICD-10: PE - I26, 
I26.99, DVT - I80, I82, I82.2) within 90days after surgery. Patients’ characteristics 
including sex, age and preoperative comobidities were defined using the HIRA 
database from 2007 to 2010. We compare the risk for VTE between hip and knee 
arthroplasty using logistic regression model in patients without VTE history and VTE 
chemoprophylaxis use . Results: A total of 38,024 patients had HA or KA arthro-
plasty in Korea in 2010 (HA 11,908 patients, KA 26,116 patients). KA was associated 
with an increased risk of DVT [aOR= 1.3; 95% CI= (1-1.7), p-value= 0.048], but KA was 
associated with a decreased risk of PE compared with HA [aOR= 0.5; 95% CI= (0.3-0.7), 
p-value< 0.001]. ConClusions: This study suggest that the risk of PE was high in 
HA rather than KA, but the risk of DVT was high in KA rather than HA. These results 
were due to differences in pathogenesis of DVT or PE.
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objeCtives: To investigate the correlation between prognostic factors and non 
prosthetic fracture related treatments following internal fixation of femoral neck 
fractures in elderly patients. Methods: This retrospective observational cohort 
study data were collected from the Hungarian National Health Insurance Fund 
Administration and from the health care provider institutes based on S7200 ICD-10 
codes. The patients with femoral neck fractures following internal fixation aged 60 
years or older were provided in 2000. The secondary non prosthetic fracture related 
treatments during the 8 year follow-up period were registered. Of the prognostic 
factors, age, gender, type of fracture and surgical intervention, season and day of 
the primary surgery, surgical delay and the accompanying diseases were evaluated. 
Statistical analyses were performed using multivariate Cox regression models and 
Kaplan Meier survival methods. Results: A total of 3306 patients met the criteria. 
The mean of age was 78.04 years (SD:8.59). The non-prosthetic fracture related treat-
ment was performed in 307 patients (9.3%). With Cox regression analysis, significant 
correlation was revealed between the incidence of non prosthetic treatment and 
younger age (year, HR= 0.978), surgical delay (12-24h vs 0-6h, HR= 1.730; 24h+ vs 0-6h, 
HR= 1.578), season of primary osteosynthesis (winter vs summer, HR= 0.707; fall vs 
summer, HR= 0.638), type of primary surgical intervention (screw vs DHS fixation, 
HR= 2.096; femoral neck nailing vs DHS fixation, HR= 3.223; Ender nailing vs DHS 
fixation, HR= 4.515) and type of femoral neck fracture (intracapsular displaced vs 
intracapsular undisplaced, HR= 1.360; extracapsular vs intracapsular undisplaced, 
HR= 1.634). There was no significant effect of the day of primary surgery, the gender 
and the presence of comorbidities on the incidence of further surgical interven-
tions. ConClusions: We have demonstrated that summertime primary surgical 
intervention, delay of surgery longer than 12 hours, type of femoral neck fracture 
and method of fixation are independent predictors of non prosthetic further treat-
ment of femoral neck fractures.
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objeCtives: To analyse the budget impact of introducing biosimilar infliximab 
for the treatment of rheumatoid arthritis in six central European countries’ –
Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovakia - health care 
systems. Methods: This budget impact model estimates the potential impact of 
the biosimilar infliximab on the health care budget over a three year time frame. 
The model considers third-party payer perspective. A spreadsheet-based country 
specific dynamic population model was developed. The model functioned in quarter 
year time units according to the three months long evaluation period. The model 
tracked the movement of the RA population between main states: 1) on synthetic 
DMARD; 2) on infliximab; 3) on biosimilar infliximab; 4) TNF inhibitors other than 
infliximab; and 5) biologics other than TNF inhibitor. Switching between biologics 
and biosimilar infliximab was taken into consideration too. Scenario analyses were 
conducted, different rate of interchanging and switching were considered. A -25% 
percentage price difference was assumed for biosimilar infliximab compared to 
originator infliximab. The budget impact was calculated as the difference in the 
total cost of the scenarios with and without biosimilar infliximab in each year of the 
